No abstract available
MeSH terms
-
Advertising / legislation & jurisprudence
-
Advisory Committees
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Arthritis / drug therapy
-
Cardiovascular Diseases / chemically induced*
-
Celecoxib
-
Clinical Trials as Topic
-
Cyclooxygenase Inhibitors / adverse effects*
-
Cyclooxygenase Inhibitors / therapeutic use
-
Drug Approval*
-
Drug Industry
-
Drug Labeling
-
Humans
-
Isoxazoles / adverse effects
-
Isoxazoles / therapeutic use
-
Lactones / adverse effects
-
Lactones / therapeutic use
-
Product Surveillance, Postmarketing*
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Sulfonamides / adverse effects
-
Sulfonamides / therapeutic use
-
Sulfones / adverse effects
-
Sulfones / therapeutic use
-
United States
-
United States Food and Drug Administration*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase Inhibitors
-
Isoxazoles
-
Lactones
-
Pyrazoles
-
Sulfonamides
-
Sulfones
-
rofecoxib
-
valdecoxib
-
Celecoxib